SynthesisMultiple sclerosis (Houndmills, Basingstoke, England)2015
A systematic review of the incidence and prevalence of cancer in multiple sclerosis.
Synthesis in Multiple sclerosis (Houndmills, Basingstoke, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 5 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis.Journal of neurology · 2025Pooled it
- Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.Journal of neurology · 2022Pooled it
- A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications.Journal of neurology · 2021Pooled it
- Pooled it
- A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.Multiple sclerosis (Houndmills, Basingstoke, England) · 2015Pooled it
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2017Trial
- Aging with multiple sclerosis and associated prevalence, incidence, comorbidities and healthcare utilization patterns in a population based study.Scientific reports · 2026Article
- Shared Genetic Effects and Antagonistic Pleiotropy Between Multiple Sclerosis and Common Cancers.Annals of clinical and translational neurology · 2026Article
- Impact of cancer on multiple sclerosis-related healthcare and disease-modifying drug use: A multinational cohort study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Article
- Frailty in multiple sclerosis: A scoping review.Multiple sclerosis and related disorders · 2024Article
- Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.Neurology · 2024Article
- Risk of cancer development associated with disease-modifying therapies for multiple sclerosis: study protocol for a systematic review and meta-analysis of randomised and non-randomised studies.Systematic reviews · 2024Article
- Article
- [Comorbidities in multiple sclerosis and their influence on the choice of treatment].Revista de neurologia · 2024Review
- Cancer and mortality risks among people with multiple sclerosis: A population-based study in Isfahan, Iran.PloS one · 2024Article
- Risk of malignancy and the use of disease-modifying therapy in multiple sclerosis: exploring the role of DMT in a multi-center study.Frontiers in neurology · 2024Article
- Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center.Turkish journal of medical sciences · 2023Article
- Association between multiple sclerosis and prostate cancer risk: A systematic review and meta‑analysis.Oncology letters · 2023Article
- Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies.Frontiers in neurology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
Abstract
backgroundStudies of cancer incidence and prevalence in multiple sclerosis (MS) have produced conflicting results.
objectiveTo estimate the incidence and prevalence of cancer in persons with MS and review the quality of included studies.
methodsWe searched the PUBMED, SCOPUS, Web of Knowledge, and EMBASE databases, conference proceedings, and reference lists of all articles retrieved. Abstracts were screened for relevance by two reviewers. Data from included articles were captured using a standardized form, and the abstraction was verified by a second reviewer. We assessed quality of the included studies. We quantitatively assessed studies using the I (2) statistic, and conducted meta-analyses for population-based studies.
resultsWe identified 38 studies. Estimates for incidence and prevalence varied substantially for most cancers. In population-based studies, cervical, breast, and digestive cancers had the highest incidence. The risk of meningiomas and urinary system cancers appeared higher than expected, while the risks of pancreatic, ovarian, prostate and testicular cancer were lower than expected.
conclusionThe complexity of understanding cancer risk in MS is augmented by inconsistencies in study design, and the relative paucity of age, sex and ethnicity-specific risk estimates from which the strong impact of age on the incidence of cancers can be assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.